Hypokalemia + Low Ionised Calcium in a 22-year-old (No Diarrhoea, No Vomiting, No Medications)

1. Hypomagnesaemia — The Central Unifying Cause

• Mg²⁺ depletion releases the intracellular block on the ROMK apical K⁺ secretory channel in the distal nephron → uncontrolled renal K⁺ wasting
• The hypokalemia is refractory to K⁺ supplementation alone until Mg²⁺ is corrected — Brenner & Rector's The Kidney, p. 752

• At serum Mg²⁺ < 0.4 mmol/L: impaired PTH secretion (chief cells require Mg²⁺ for exocytosis)
• Impaired synthesis of 1,25(OH)₂D (calcitriol)
• End-organ resistance to both PTH and vitamin D
• → Low ionised calcium that corrects rapidly (within 24 h) with Mg²⁺ repletion — Harrison's Principles of Internal Medicine 22e, p. 3310; Brenner & Rector, p. 3126

2. Gitelman Syndrome (Most Likely Genetic Cause in a Young Normotensive Patient)

• Autosomal recessive loss-of-function mutations in SLC12A3 (thiazide-sensitive NaCl cotransporter, DCT)
• Presents in late childhood to adulthood, often with mild symptoms (fatigue, cramps, salt craving)
• Electrolyte pattern: hypokalemia + metabolic alkalosis + hypomagnesaemia + hypocalciuria
• BP is normal to low — a key distinguishing feature
• Hypocalciuria (not hypocalcaemia) is classic; however, secondary hypomagnesaemia can produce low ionised calcium via the PTH mechanism above — NKF Primer on Kidney Diseases 8e, p. 176

3. Bartter Syndrome (Type V — CaSR Activating Mutation)

• Classic Bartter (Types I–IV): hypokalemia, metabolic alkalosis, normal-to-low BP, hypercalciuria, normal Mg²⁺ — does not typically cause hypocalcaemia
• Type V (CaSR-activating mutation): Activating mutations of the calcium-sensing receptor → suppressed PTH → hypocalcaemia + hypercalciuria, and CaSR activation on TAL inhibits ROMK → K⁺ wasting → hypokalemia
• This is also classified as Autosomal Dominant Hypocalcaemia (ADH) and represents a rare but important cause of the exact combination seen here — NKF Primer, p. 176

4. Autosomal Dominant Hypocalcaemia (ADH) / Activating CaSR Mutation (standalone)

• Gain-of-function mutations in CASR → CaSR set point shifted left → PTH suppressed at normal calcium → low ionised Ca²⁺
• CaSR activation in the kidney also causes renal K⁺ wasting and hypokalemia
• No GI losses, no medications needed to explain it
• Presents in young adults; family history of hypocalcaemia may be present

5. Vitamin D Deficiency / Osteomalacia

• Severe vitamin D deficiency → low ionised calcium (reduced intestinal Ca²⁺ absorption)
• Secondary hyperparathyroidism increases phosphaturia and can contribute to electrolyte shifts
• Hypokalemia is not a direct consequence but may co-exist via secondary mechanisms or eating disorder
• Particularly relevant in a young person with restricted diet or limited sun exposure

6. Hypoparathyroidism

• Primary (autoimmune, DiGeorge/22q11.2 deletion) or post-surgical
• Low PTH → low ionised Ca²⁺, hyperphosphataemia
• Hypokalemia not a primary feature but may occur with:
  • Concomitant hypomagnesaemia (Mg²⁺ required for PTH secretion — chicken-and-egg)
  • Autoimmune polyendocrine syndrome (APS-1) with associated adrenal/tubular involvement

7. Renal Tubular Acidosis (Type I / Distal RTA)

• Causes hypokalemia (urinary K⁺ wasting) + hypocalciuria and hypocalcaemia (acidosis mobilises bone Ca²⁺ acutely but chronic bone demineralisation leads to low ionised Ca²⁺)
• Presents with normal BP, metabolic acidosis (not alkalosis), nephrocalcinosis
• Young patients with incomplete RTA may have subtle acidosis

8. Familial Hypomagnesaemia with Secondary Hypocalcaemia (HSH)

• TRPM6 gene mutations → defective intestinal and renal Mg²⁺ reabsorption → profound hypomagnesaemia → secondary hypocalcaemia (via PTH impairment)
• Usually presents in infancy with seizures, but milder variants can present in young adulthood
• Would explain both abnormalities together — Harrison's, p. 3310; Brenner & Rector, p. 2015

Practical Approach: Investigations to Prioritise

Step 1:  Serum magnesium — if low, this is the diagnosis driver
Step 2:  PTH, 25-OH vitamin D, phosphate
Step 3:  Urine K⁺ (FEK or TTKG) — renal vs. non-renal K⁺ loss
Step 4:  Urine Ca²⁺/Cr ratio — hypocalciuria (Gitelman, CaSR) vs. hypercalciuria (Bartter)
Step 5:  Urine Mg²⁺ — if urine Mg²⁺ high despite low serum → renal wasting (tubular disorder)
Step 6:  Blood gas — alkalosis (Gitelman/Bartter) vs. acidosis (RTA)
Step 7:  Genetic panel if tubular disorder suspected (SLC12A3, CASR, TRPM6)

Summary Table

Refractory Hypokalemia + Low Ionised Calcium → Hypomagnesaemia Until Proven Otherwise

Why Hypomagnesaemia Makes Hypokalemia Refractory

"Hypomagnesemic patients are clinically refractory to K⁺ replacement in the absence of Mg²⁺ repletion." — Harrison's Principles of Internal Medicine 22e

"Patients are often refractory to potassium repletion until their magnesium deficit is corrected." — Brenner & Rector's The Kidney

"Hypokalemic patients who are refractory to potassium replacement are likely to also be hypomagnesemic." — Rosen's Emergency Medicine

And the Hypocalcaemia?

• PTH secretion requires Mg²⁺ (exocytosis from chief cells fails at Mg²⁺ < 0.4 mmol/L)
• End-organ resistance to PTH and impaired 1,25(OH)₂D synthesis
• Both the hypokalemia and hypocalcaemia correct only after Mg²⁺ is repleted

"Refractory hypokalemia and hypocalcemia are rapidly corrected by supplementation of magnesium." — NKF Primer on Kidney Diseases 8e

What to Do Now

Treatment Principle

Normal Mg²⁺ + Refractory Hypokalemia + Low Ionised Calcium

The Leading Diagnosis: Autosomal Dominant Hypocalcaemia with Hypercalciuria (ADHH) — Bartter Syndrome Type 5 / Activating CaSR Mutation

1. Parathyroid gland — normally PTH secretion is suppressed when CaSR detects high Ca²⁺
2. Basolateral membrane of the thick ascending limb (TAL) and distal nephron

"Children with activating mutations in either the CaSR or the G protein coupled to CaSR display a phenotype characterised by hypokalemia, hypercalciuria, and hypoparathyroidism... CaSR activation also inhibits sodium and chloride reabsorption. Hence patients with these mutations can also demonstrate a Bartter phenotype — this is why these mutations have also been referred to as Bartter syndrome type 5." — Brenner & Rector's The Kidney

• Young (22 y/o) — congenital/genetic condition, often diagnosed in young adulthood
• Low ionised Ca²⁺ — suppressed PTH
• Refractory hypokalemia — ROMK disinhibition in TAL
• Normal magnesium — distinguishes from Gitelman (which is uniformly hypomagnesaemic)
• No medications, no GI losses
• Family history of hypocalcaemia may be present (autosomal dominant)

Also Consider: Distal Renal Tubular Acidosis (Type 1)

• Loss-of-function mutations in H⁺-ATPase subunits (ATP6V1B1, ATP6V0A4) or AE1 (SLC4A1)
• Defective proton secretion in collecting duct → metabolic acidosis + urinary K⁺ wasting → hypokalemia
• Chronic acidosis mobilises bone calcium and impairs renal Ca²⁺ reabsorption → low ionised Ca²⁺, secondary hyperparathyroidism
• Associated with nephrocalcinosis and hypercalciuria
• Hypokalemia can be refractory if acidosis is not corrected (alkali therapy is primary treatment)
• Normal Mg²⁺ is consistent
• Blood gas would show non-anion gap metabolic acidosis — this should be checked

Summary of Remaining Differential with Normal Mg²⁺

Next Investigations

1. Urine calcium/creatinine ratio
   → High: favours CaSR mutation (ADHH/Bartter type 5) or dRTA
   → Low: less likely CaSR mutation

2. Serum PTH
   → Low/suppressed: CaSR mutation or primary hypoparathyroidism
   → High/normal: dRTA or secondary hyperparathyroidism

3. Blood gas + serum bicarbonate
   → Metabolic alkalosis: CaSR/Bartter phenotype
   → Non-anion gap metabolic acidosis: distal RTA

4. Serum phosphate
   → High phosphate + low PTH: hypoparathyroidism

5. Renal ultrasound — nephrocalcinosis (dRTA, Bartter)

6. CASR gene sequencing — confirm activating mutation

Dual Antiplatelet Therapy in ACS: Route of Administration

Aspirin

• Swallowed whole: absorbed in the small intestine; platelet inhibition takes ~60 minutes
• Chewed: begins absorption through the buccal/gastric mucosa immediately; platelet inhibition achieved in ~14–20 minutes
• Sublingual: while technically faster than swallowing whole, chewing is equivalent or superior and is the standard recommendation

"Chewing an aspirin tablet is the most effective way of accelerating absorption of aspirin into the blood and shortening the time required for an antiplatelet effect." (PMID 10468077)

P2Y12 Inhibitors (Ticagrelor, Clopidogrel, Prasugrel)

• These are tablet formulations only — no sublingual preparation exists
• They are absorbed in the GI tract; sublingual mucosa lacks the necessary surface area and transporter mechanisms for adequate absorption of these molecules
• For patients unable to swallow (e.g. intubated, vomiting), crushed tablets via nasogastric tube is the accepted alternative — demonstrated to maintain therapeutic plasma levels

Summary